Verizon broadens mobile health offerings with new ‘Virtual Visits’
NEW YORK — Verizon is expanding its mobile health solutions portfolio with the launch of its new Verizon Virtual Visits, which is designed to provide an easy, convenient and cost-effective way for patients to be seen remotely by a clinician for a cold, flu, sore throat or other simple, acute condition via video on their smartphone, tablet or computer.
"We are seeing a shift in how care is delivered in the United States. With Verizon Virtual Visits, patients and providers alike can benefit from the use of technology to provide medical care via an enterprise-class technology solution developed with the security, performance and reliability essential to healthcare delivery,” said Rich Black, VP healthcare practice for Verizon. "We believe our latest mobile health offering can go a long way to enable a more efficient and effective U.S. healthcare system.”
How it works: Patients can connect online with a clinician through an app on their smartphone or tablet, or via a Web portal. Once logged in, patients are taken through a set of health-related questions, followed by a discussion with a clinician, who evaluates the patient's condition and provides an appropriate care plan.
Clinicians also can use the platform to electronically send a prescription to the pharmacy of the patient's choosing, where legally permitted.
Data shared between the clinician and the patient is encrypted during the online visit, as well as afterward when the data is stored in Verizon's HIPAA-enabled Cloud.
Novo Nordisk teams with NBA’s Dominique Wilkins to launch Dominique’s Diabetes Dream Team
PLAINSBORO, N.J. — Novo Nordisk is teaming up with NBA Hall of Famer Dominique Wilkins to launch Dominique’s Diabetes Dream Team, a national initiative to help adults with Type 2 diabetes customize a "full-court" approach to managing the everyday challenges of the disease.
Dominique’s Diabetes Dream Team will highlight three key components of a successful diabetes management plan: a balanced diet, regular exercise and proper medication, as needed. Dominique’s own team is comprised of his physicians, a diabetes educator, a nutritionist and a fitness expert, who together offer him guidance on daily diabetes management.
"Diabetes is a complex disease, and it takes a team to get the best results. When I was diagnosed with the disease, I formed my own ‘Diabetes Dream Team,’" Wilkins said. "They’ve taught me that small, simple changes can make a big difference, and I am excited to partner with Novo Nordisk to help others think differently about managing their diabetes."
Adults with Type 2 diabetes can visit DiabetesDreamTeam.com to download a copy of Dominique’s "Diabetes Coaches’ Clipboard." The clipboard is full of insider tips on diabetes management from Dominique and his team of experts.
Dominique also will be in attendance at select diabetes conferences nationwide, where he and his team will share personal stories and advice on how people can better manage their diabetes with the help of their own Diabetes Dream Team.
"The way Dominique has learned to manage his Type 2 diabetes sets a good example for anyone living with the disease," said Camille Lee, SVP diabetes marketing at Novo Nordisk. "Novo Nordisk wants to share his success to benefit others who face daily struggles with Type 2 diabetes."
Report: Pharmaceutical sales to grow 5.1% on average through 2020
LONDON — Worldwide prescription drug sales are expected to exceed the trillion dollar mark by 2020, according to Evaluate's "World Preview 2014, Outlook to 2020" report released Wednesday. Evaluate projects the pharma industry to grow, on average, 5.1% per year from 2013 to 2020.
Biologicals will make up 52% of the top 100 prescription and OTC drug sales in 2020, Evaluate reported. Oncology will set record high growth with an 11.2% compound annual growth rate to 2020. Novartis is expected to remain the top company by global drug sales in 2020, Evaluate reported. Teva Pharmaceuticals was the leading generic drug maker in 2013.
“This much improved growth outlook comes as welcome news after two years of actual sales stagnation,” stated Paul Hills, report author and Evaluate’s head of operations. “While the patent cliff is now but a distant memory, a new debate over drug pricing is stirring up controversy. This will only intensify as the industry continues to shift away from primary care and new technology waves offer innovative products that potentially take costs out of healthcare.”
The “World Preview 2014, Outlook to 2020” report, based on market intelligence and consensus forecasts from EvaluatePharma, can be downloaded at Evaluategroup.com/wp2014, the company stated.